BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32906621)

  • 1. Therapeutic Strategies Targeting DUX4 in FSHD.
    Le Gall L; Sidlauskaite E; Mariot V; Dumonceaux J
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
    Banerji CRS; Zammit PS
    EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).
    Ansseau E; Vanderplanck C; Wauters A; Harper SQ; Coppée F; Belayew A
    Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy.
    Thijssen PE; Balog J; Yao Z; Pham TP; Tawil R; Tapscott SJ; Van der Maarel SM
    Skelet Muscle; 2014; 4():19. PubMed ID: 25789155
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Sidlauskaite E; Le Gall L; Mariot V; Dumonceaux J
    J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32731450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
    Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
    Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy.
    Ganassi M; Figeac N; Reynaud M; Ortuste Quiroga HP; Zammit PS
    Front Cell Dev Biol; 2022; 10():802573. PubMed ID: 36158201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facioscapulohumeral muscular dystrophy.
    Tawil R
    Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.
    Jones TI; King OD; Himeda CL; Homma S; Chen JC; Beermann ML; Yan C; Emerson CP; Miller JB; Wagner KR; Jones PL
    Clin Epigenetics; 2015; 7(1):37. PubMed ID: 25904990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facioscapulohumeral Muscular Dystrophy.
    DeSimone AM; Pakula A; Lek A; Emerson CP
    Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV; Rosa AL
    Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
    Schätzl T; Kaiser L; Deigner HP
    Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
    Haynes P; Bomsztyk K; Miller DG
    Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and animal models for facioscapulohumeral muscular dystrophy.
    DeSimone AM; Cohen J; Lek M; Lek A
    Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
    Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
    Elife; 2015 Jan; 4():. PubMed ID: 25564732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
    Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
    Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4.
    Balog J; Thijssen PE; Shadle S; Straasheijm KR; van der Vliet PJ; Krom YD; van den Boogaard ML; de Jong A; F Lemmers RJ; Tawil R; Tapscott SJ; van der Maarel SM
    Epigenetics; 2015; 10(12):1133-42. PubMed ID: 26575099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.